Reports
Sale
Cervical Dystonia Market Size, Share, Analysis, Forecast: By Type: Retrocollis, Anterocollis, Laterocollis, Torticollis, Others; By Therapy: Oral Therapy, Intravenous, Surgery, Others; By End User: Hospitals, Homecare, Specialty Clinics, Others; Regional Analysis; Market Dynamics: Market Drivers and Constraints; Supplier Landscape; 2024-2032
Cervical Dystonia Market Outlook
The cervical dystonia market size is expected to grow at a CAGR of 5.8% during the forecast period of 2024-2032. The market is driven by the advancements in treatment options and diagnostic methods along with the heightened awareness around the condition across 8 major markets.
Cervical Dystonia Market Overview
Cervical dystonia is a neurological condition that causes involuntary contraction of the neck muscles. It can make the head and neck twist or turn into abnormal positions that can be painful to the patient. The prevalence of cervical dystonia is estimated to be 5 to 30 cases for every 100,000 individuals. In the United States, the incidence of the condition is 1.18 per 100,000 individuals annually. The number of patients suffering from this movement disorder are rising steadily, which is projected to fuel the cervical dystonia market growth in the coming years.
The market is experiencing a rise in the number of approvals from health regulatory authorities which is positively influencing the market landscape. In August 2023 , the United States Food and Drug Administration (FDA) approved Daxxify® (daxibotulinumtoxinA- lanm) to treat cervical dystonia in adults. The product, developed by a United States-based pharmaceutical company Revance Therapeutics Inc., is the first peptide-formulated and long-lasting neuromodulator designed to provide relief to patients suffering from the condition. The launch of such innovative treatment therapeutics is expected to bolster the cervical dystonia market demand.
The market is also driven by the rise in geriatric population prone to movement disorders. Moreover, increased investments by biopharmaceutical companies in research and development projects is likely to aid in the expansion of the market share. There has been a significant effort to increase awareness among the public about cervical dystonia. This includes the importance of early diagnosis, leading to improved outcomes for patients.
Cervical Dystonia Market Trends
| Key Trends | Description |
| Emergence of Neuromodulation Therapies | Neuromodulation techniques, such as deep brain stimulation (DBS), have emerged as potential treatment options for patients with cervical dystonia. |
| Improved Diagnostic Technologies | Advances in imaging techniques and the development of genetic markers have increased the diagnostic accuracy for cervical dystonia. This facilitates earlier intervention and improves patient outcomes. |
| Intensive Research Initiatives | Ongoing research aims to understand the underlying causes and mechanisms of cervical dystonia in order to develop novel therapeutics. |
| Personalized Medicine Approaches | Efforts are being made to customize treatments based on severity of symptoms, and response to previous treatments. The growing demand for personalized approaches will optimize outcomes and minimize side effects. |
Cervical Dystonia Market Segmentation
Market Breakup by Type
- Retrocollis
- Anterocollis
- Laterocollis
- Torticollis
- Others
Based on market segmentation by type, the report includes retrocollis, anterocollis, laterocollis, and torticollis, among others. Retrocollis refers to backward head tilting, anterocollis to forward tilting, laterocollis to lateral tilting, and torticollis to twisting of the neck. Each subtype may require specific interventions to manage the symptoms.
Market Breakup by Therapy
- Oral Therapy
- Intravenous
- Surgery
- Others
By therapy, the cervical dystonia market share is divided into oral therapy, intravenous treatment, and surgery, among others. These therapy options help to address the diverse needs of the patients suffering from cervical dystonia.
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
The market segmentation by end users includes hospitals, homecare, specialty clinics, and others.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
The cervical dystonia market report offers an exhaustive analysis of the regional markets expected to witness significant market growth in the forecast period. The regional segmentation includes the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China. North America holds a high market value which can be attributed to the rising geriatric population in the region. Moreover, the presence of an advanced healthcare system and the increased investment by pharmaceutical companies to develop effective therapeutics is propelling the market share in this regional market.
Cervical Dystonia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AbbVie Inc.
- Ipsen Pharma
- Galderma SA
- Revance Therapeutics Inc.
- AEON Biopharma
- Merz Pharmaceuticals
- US World Meds
- Tercica Inc.
- Boston Scientific Corporation
- Allergan Inc.
- Solstice neurosciences lnc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Therapy |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Cervical Dystonia Market Report
- How will the market landscape evolve in the forecast period?
- What are the key drivers and challenges influencing market growth?
- What are the prevailing treatment therapies available for cervical dystonia, and how do they compare in terms of efficacy, safety, and cost?
- Which therapy type will dominate the market segment in the coming years?
- What are the emerging trends and developments in the diagnosis, treatment, and management of cervical dystonia?
- How does the regulatory landscape impact the approval and commercialization of therapies for cervical dystonia?
- What are the unmet needs and challenges in the diagnosis, treatment, and management of cervical dystonia?
- What is the market outlook for cervical dystonia in different regions?
- Which regional market holds the highest cervical dystonia market value?
- What are the implications of healthcare policies, reimbursement frameworks, and patient awareness campaigns on the market?
- How do demographic factors influence the prevalence and management of cervical dystonia?
- What are the opportunities for innovation and advancements in cervical dystonia treatment and management?
- How are patient preferences shaping the evolution of treatment strategies?
- What are the strategies of the key market players for product development, marketing, and market expansion?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cervical Dystonia Market Overview – 8 Major Markets
3.1 Cervical Dystonia Market Historical Value (2017-2023)
3.2 Cervical Dystonia Market Forecast Value (2024-2032)
4 Cervical Dystonia Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Cervical Dystonia Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.5 China Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
7 Cervical Dystonia Market Landscape – 8 Major Markets
7.1 Cervical Dystonia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cervical Dystonia: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Therapy
8 Cervical Dystonia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Cervical Dystonia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Cervical Dystonia Market Segmentation (2017-2032) - 8 Major Markets
11.1 Cervical Dystonia Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Retrocollis
11.1.3 Anterocollis
11.1.4 Laterocollis
11.1.5 Torticollis
11.1.6 Others
11.2 Cervical Dystonia Market (2017-2032) by Therapy
11.2.1 Market Overview
11.2.2 Oral Therapy
11.2.3 Intravenous
11.2.4 Surgery
11.2.5 Others
11.3 Cervical Dystonia Market (2017-2032) by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Homecare
11.3.4 Specialty Clinics
11.3.5 Others
11.4 Cervical Dystonia Market (2017-2032) by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 China
12 United States Cervical Dystonia Market (2017-2032)
12.1 United States Cervical Dystonia Market Historical Value (2017-2023)
12.2 United States Cervical Dystonia Market Forecast Value (2024-2032)
12.3 United States Cervical Dystonia Market (2017-2032) by Type
12.3.1 Market Overview
12.3.2 Medication
12.3.3 Organ Transplantation
12.3.4 Oxygen Therapy
12.3.5 Others
12.4 United States Cervical Dystonia Market (2017-2032) by Therapy
12.4.1 Market Overview
12.4.2 Idiopathic pulmonary fibrosis
12.4.3 Hepatic cirrhosis
12.4.4 Renal fibrosis
12.4.5 Cutaneous fibrosis
12.4.6 Others
13 EU-4 and United Kingdom Cervical Dystonia Market (2017-2032)
13.1 EU-4 and United Kingdom Cervical Dystonia Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Cervical Dystonia Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Dystonia Market (2017-2032) by Type
13.3.1 Market Overview
13.3.2 Medication
13.3.3 Organ Transplantation
13.3.4 Oxygen Therapy
13.3.5 Others
13.4 EU-4 and United Kingdom Dystonia Market (2017-2032) by Therapy
13.4.1 Market Overview
13.4.2 Idiopathic pulmonary fibrosis
13.4.3 Hepatic cirrhosis
13.4.4 Renal fibrosis
13.4.5 Cutaneous fibrosis
13.4.6 Others
14 Japan Cervical Dystonia Market
14.1 Japan Cervical Dystonia Market Historical Value (2017-2023)
14.2 Japan Cervical Dystonia Market Forecast Value (2024-2032)
14.3 Japan Cervical Dystonia Market (2017-2032) by Type
14.3.1 Market Overview
14.3.2 Medication
14.3.3 Organ Transplantation
14.3.4 Oxygen Therapy
14.3.5 Others
14.4 Japan Cervical Dystonia Market (2017-2032) by Therapy
14.4.1 Market Overview
14.4.2 Idiopathic pulmonary fibrosis
14.4.3 Hepatic cirrhosis
14.4.4 Renal fibrosis
14.4.5 Cutaneous fibrosis
14.4.6 Others
15 China Cervical Dystonia Market
15.1 China Cervical Dystonia Market (2017-2032) Historical Value (2017-2023)
15.2 China Cervical Dystonia Market (2017-2032) Forecast Value (2024-2032)
15.3 China Cervical Dystonia Market (2017-2032) by Type
15.3.1 Market Overview
15.3.2 Medication
15.3.3 Organ Transplantation
15.3.4 Oxygen Therapy
15.3.5 Others
15.4 China Cervical Dystonia Market (2017-2032) by Therapy
15.4.1 Market Overview
15.4.2 Idiopathic pulmonary fibrosis
15.4.3 Hepatic cirrhosis
15.4.4 Renal fibrosis
15.4.5 Cutaneous fibrosis
15.4.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 AbbVie Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 Ipsen Pharma
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Galderma SA
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Revance Therapeutics Inc.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 AEON Biopharma
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Merz Pharmaceuticals
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 US World Meds
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Tercica Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Boston Scientific Corporation
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Allergan Inc.
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Solstice neurosciences lnc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
List not exhaustive
23 Cervical Dystonia Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
*The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032, driven by the advancements in treatment options and diagnostic methods across the 8 major markets.
Increased investments supporting the development of effective therapeutics and rising healthcare expenditure are fuelling market demand.
One of the significant trends in the market is the growth in approvals by the health regulatory agencies. In August 2023, the Food and Drug Administration (FDA) approved Revance Therapeutics’ Daxxify® (daxibotulinumtoxinA- lanm) to treat cervical dystonia in adults.
Based on the type, the market is segmented into retrocollis, anterocollis, laterocollis, and torticollis, among others.
Major end users of the market include hospitals, homecare, specialty clinics, and others.
Therapies for cervical dystonia include oral therapy, intravenous treatment, and surgery, among others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and China.
Key players involved in the market are AbbVie Inc., Ipsen Pharma, Galderma SA, Revance Therapeutics Inc., AEON Biopharma, Merz Pharmaceuticals, US World Meds, Tercica Inc., Boston Scientific Corporation, Allergan Inc., and Solstice neurosciences lnc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER